1 Market Overview

1.1 Product Overview and Scope of Neurodegenerative Disease

1.2 Classification of Neurodegenerative Disease by Type

1.2.1 Overview: Global Neurodegenerative Disease Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Neurodegenerative Disease Revenue Market Share by Type in 2021

1.2.3 NMDA

1.2.4 SSRIs

1.2.5 Dopamine Inhibitors

1.3 Global Neurodegenerative Disease Market by Application

1.3.1 Overview: Global Neurodegenerative Disease Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Parkinson’s Disease

1.3.3 Huntington Disease

1.3.4 Amyotrophic Lateral Sclerosis

1.3.5 Alzheimer’s Disease

1.4 Global Neurodegenerative Disease Market Size & Forecast

1.5 Global Neurodegenerative Disease Market Size and Forecast by Region

1.5.1 Global Neurodegenerative Disease Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Neurodegenerative Disease Market Size by Region, (2017-2022)

1.5.3 North America Neurodegenerative Disease Market Size and Prospect (2017-2028)

1.5.4 Europe Neurodegenerative Disease Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Neurodegenerative Disease Market Size and Prospect (2017-2028)

1.5.6 South America Neurodegenerative Disease Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Neurodegenerative Disease Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Neurodegenerative Disease Market Drivers

1.6.2 Neurodegenerative Disease Market Restraints

1.6.3 Neurodegenerative Disease Trends Analysis

2 Company Profiles

2.1 Novartis

2.1.1 Novartis Details

2.1.2 Novartis Major Business

2.1.3 Novartis Neurodegenerative Disease Product and Solutions

2.1.4 Novartis Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Novartis Recent Developments and Future Plans

2.2 Pfizer

2.2.1 Pfizer Details

2.2.2 Pfizer Major Business

2.2.3 Pfizer Neurodegenerative Disease Product and Solutions

2.2.4 Pfizer Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Pfizer Recent Developments and Future Plans

2.3 Merck Serono

2.3.1 Merck Serono Details

2.3.2 Merck Serono Major Business

2.3.3 Merck Serono Neurodegenerative Disease Product and Solutions

2.3.4 Merck Serono Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Merck Serono Recent Developments and Future Plans

2.4 Biogen Idec

2.4.1 Biogen Idec Details

2.4.2 Biogen Idec Major Business

2.4.3 Biogen Idec Neurodegenerative Disease Product and Solutions

2.4.4 Biogen Idec Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Biogen Idec Recent Developments and Future Plans

2.5 TEVA

2.5.1 TEVA Details

2.5.2 TEVA Major Business

2.5.3 TEVA Neurodegenerative Disease Product and Solutions

2.5.4 TEVA Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 TEVA Recent Developments and Future Plans

2.6 UCB

2.6.1 UCB Details

2.6.2 UCB Major Business

2.6.3 UCB Neurodegenerative Disease Product and Solutions

2.6.4 UCB Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 UCB Recent Developments and Future Plans

2.7 Boehringer Ingelheim

2.7.1 Boehringer Ingelheim Details

2.7.2 Boehringer Ingelheim Major Business

2.7.3 Boehringer Ingelheim Neurodegenerative Disease Product and Solutions

2.7.4 Boehringer Ingelheim Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Boehringer Ingelheim Recent Developments and Future Plans

2.8 Sanofi

2.8.1 Sanofi Details

2.8.2 Sanofi Major Business

2.8.3 Sanofi Neurodegenerative Disease Product and Solutions

2.8.4 Sanofi Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Sanofi Recent Developments and Future Plans

2.9 GlaxoSmithKline

2.9.1 GlaxoSmithKline Details

2.9.2 GlaxoSmithKline Major Business

2.9.3 GlaxoSmithKline Neurodegenerative Disease Product and Solutions

2.9.4 GlaxoSmithKline Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 GlaxoSmithKline Recent Developments and Future Plans

2.10 Livzon Pharmaceutical

2.10.1 Livzon Pharmaceutical Details

2.10.2 Livzon Pharmaceutical Major Business

2.10.3 Livzon Pharmaceutical Neurodegenerative Disease Product and Solutions

2.10.4 Livzon Pharmaceutical Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Livzon Pharmaceutical Recent Developments and Future Plans

2.11 Haisco Pharmaceutical

2.11.1 Haisco Pharmaceutical Details

2.11.2 Haisco Pharmaceutical Major Business

2.11.3 Haisco Pharmaceutical Neurodegenerative Disease Product and Solutions

2.11.4 Haisco Pharmaceutical Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Haisco Pharmaceutical Recent Developments and Future Plans

2.12 Jingxin Pharmaceutical

2.12.1 Jingxin Pharmaceutical Details

2.12.2 Jingxin Pharmaceutical Major Business

2.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Product and Solutions

2.12.4 Jingxin Pharmaceutical Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Jingxin Pharmaceutical Recent Developments and Future Plans

2.13 Dongcheng Biochemicals

2.13.1 Dongcheng Biochemicals Details

2.13.2 Dongcheng Biochemicals Major Business

2.13.3 Dongcheng Biochemicals Neurodegenerative Disease Product and Solutions

2.13.4 Dongcheng Biochemicals Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Dongcheng Biochemicals Recent Developments and Future Plans

2.14 Hisun Pharmaceutical

2.14.1 Hisun Pharmaceutical Details

2.14.2 Hisun Pharmaceutical Major Business

2.14.3 Hisun Pharmaceutical Neurodegenerative Disease Product and Solutions

2.14.4 Hisun Pharmaceutical Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Hisun Pharmaceutical Recent Developments and Future Plans

2.15 Luye Pharma

2.15.1 Luye Pharma Details

2.15.2 Luye Pharma Major Business

2.15.3 Luye Pharma Neurodegenerative Disease Product and Solutions

2.15.4 Luye Pharma Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Luye Pharma Recent Developments and Future Plans

2.16 Ark Pharmaceutical

2.16.1 Ark Pharmaceutical Details

2.16.2 Ark Pharmaceutical Major Business

2.16.3 Ark Pharmaceutical Neurodegenerative Disease Product and Solutions

2.16.4 Ark Pharmaceutical Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Ark Pharmaceutical Recent Developments and Future Plans

2.17 Kanghong Pharmaceutical

2.17.1 Kanghong Pharmaceutical Details

2.17.2 Kanghong Pharmaceutical Major Business

2.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Product and Solutions

2.17.4 Kanghong Pharmaceutical Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 Kanghong Pharmaceutical Recent Developments and Future Plans

2.18 Huahai Pharmaceutical

2.18.1 Huahai Pharmaceutical Details

2.18.2 Huahai Pharmaceutical Major Business

2.18.3 Huahai Pharmaceutical Neurodegenerative Disease Product and Solutions

2.18.4 Huahai Pharmaceutical Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.18.5 Huahai Pharmaceutical Recent Developments and Future Plans

2.19 BORA PHARMACEUTICALS

2.19.1 BORA PHARMACEUTICALS Details

2.19.2 BORA PHARMACEUTICALS Major Business

2.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Product and Solutions

2.19.4 BORA PHARMACEUTICALS Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.19.5 BORA PHARMACEUTICALS Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Neurodegenerative Disease Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Neurodegenerative Disease Players Market Share in 2021

3.2.2 Top 10 Neurodegenerative Disease Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Neurodegenerative Disease Players Head Office, Products and Services Provided

3.4 Neurodegenerative Disease Mergers & Acquisitions

3.5 Neurodegenerative Disease New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Neurodegenerative Disease Revenue and Market Share by Type (2017-2022)

4.2 Global Neurodegenerative Disease Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Neurodegenerative Disease Revenue Market Share by Application (2017-2022)

5.2 Global Neurodegenerative Disease Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Neurodegenerative Disease Revenue by Type (2017-2028)

6.2 North America Neurodegenerative Disease Revenue by Application (2017-2028)

6.3 North America Neurodegenerative Disease Market Size by Country

6.3.1 North America Neurodegenerative Disease Revenue by Country (2017-2028)

6.3.2 United States Neurodegenerative Disease Market Size and Forecast (2017-2028)

6.3.3 Canada Neurodegenerative Disease Market Size and Forecast (2017-2028)

6.3.4 Mexico Neurodegenerative Disease Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Neurodegenerative Disease Revenue by Type (2017-2028)

7.2 Europe Neurodegenerative Disease Revenue by Application (2017-2028)

7.3 Europe Neurodegenerative Disease Market Size by Country

7.3.1 Europe Neurodegenerative Disease Revenue by Country (2017-2028)

7.3.2 Germany Neurodegenerative Disease Market Size and Forecast (2017-2028)

7.3.3 France Neurodegenerative Disease Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Neurodegenerative Disease Market Size and Forecast (2017-2028)

7.3.5 Russia Neurodegenerative Disease Market Size and Forecast (2017-2028)

7.3.6 Italy Neurodegenerative Disease Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Neurodegenerative Disease Revenue by Type (2017-2028)

8.2 Asia-Pacific Neurodegenerative Disease Revenue by Application (2017-2028)

8.3 Asia-Pacific Neurodegenerative Disease Market Size by Region

8.3.1 Asia-Pacific Neurodegenerative Disease Revenue by Region (2017-2028)

8.3.2 China Neurodegenerative Disease Market Size and Forecast (2017-2028)

8.3.3 Japan Neurodegenerative Disease Market Size and Forecast (2017-2028)

8.3.4 South Korea Neurodegenerative Disease Market Size and Forecast (2017-2028)

8.3.5 India Neurodegenerative Disease Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Neurodegenerative Disease Market Size and Forecast (2017-2028)

8.3.7 Australia Neurodegenerative Disease Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Neurodegenerative Disease Revenue by Type (2017-2028)

9.2 South America Neurodegenerative Disease Revenue by Application (2017-2028)

9.3 South America Neurodegenerative Disease Market Size by Country

9.3.1 South America Neurodegenerative Disease Revenue by Country (2017-2028)

9.3.2 Brazil Neurodegenerative Disease Market Size and Forecast (2017-2028)

9.3.3 Argentina Neurodegenerative Disease Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Neurodegenerative Disease Revenue by Type (2017-2028)

10.2 Middle East & Africa Neurodegenerative Disease Revenue by Application (2017-2028)

10.3 Middle East & Africa Neurodegenerative Disease Market Size by Country

10.3.1 Middle East & Africa Neurodegenerative Disease Revenue by Country (2017-2028)

10.3.2 Turkey Neurodegenerative Disease Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Neurodegenerative Disease Market Size and Forecast (2017-2028)

10.3.4 UAE Neurodegenerative Disease Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Neurodegenerative Disease Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Neurodegenerative Disease Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Neurodegenerative Disease Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Neurodegenerative Disease Revenue (USD Million) by Region (2017-2022)

Table 5. Global Neurodegenerative Disease Revenue Market Share by Region (2023-2028)

Table 6. Novartis Corporate Information, Head Office, and Major Competitors

Table 7. Novartis Major Business

Table 8. Novartis Neurodegenerative Disease Product and Solutions

Table 9. Novartis Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Pfizer Corporate Information, Head Office, and Major Competitors

Table 11. Pfizer Major Business

Table 12. Pfizer Neurodegenerative Disease Product and Solutions

Table 13. Pfizer Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Merck Serono Corporate Information, Head Office, and Major Competitors

Table 15. Merck Serono Major Business

Table 16. Merck Serono Neurodegenerative Disease Product and Solutions

Table 17. Merck Serono Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Biogen Idec Corporate Information, Head Office, and Major Competitors

Table 19. Biogen Idec Major Business

Table 20. Biogen Idec Neurodegenerative Disease Product and Solutions

Table 21. Biogen Idec Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. TEVA Corporate Information, Head Office, and Major Competitors

Table 23. TEVA Major Business

Table 24. TEVA Neurodegenerative Disease Product and Solutions

Table 25. TEVA Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. UCB Corporate Information, Head Office, and Major Competitors

Table 27. UCB Major Business

Table 28. UCB Neurodegenerative Disease Product and Solutions

Table 29. UCB Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors

Table 31. Boehringer Ingelheim Major Business

Table 32. Boehringer Ingelheim Neurodegenerative Disease Product and Solutions

Table 33. Boehringer Ingelheim Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Sanofi Corporate Information, Head Office, and Major Competitors

Table 35. Sanofi Major Business

Table 36. Sanofi Neurodegenerative Disease Product and Solutions

Table 37. Sanofi Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 39. GlaxoSmithKline Major Business

Table 40. GlaxoSmithKline Neurodegenerative Disease Product and Solutions

Table 41. GlaxoSmithKline Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Livzon Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 43. Livzon Pharmaceutical Major Business

Table 44. Livzon Pharmaceutical Neurodegenerative Disease Product and Solutions

Table 45. Livzon Pharmaceutical Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Haisco Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 47. Haisco Pharmaceutical Major Business

Table 48. Haisco Pharmaceutical Neurodegenerative Disease Product and Solutions

Table 49. Haisco Pharmaceutical Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Jingxin Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 51. Jingxin Pharmaceutical Major Business

Table 52. Jingxin Pharmaceutical Neurodegenerative Disease Product and Solutions

Table 53. Jingxin Pharmaceutical Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Dongcheng Biochemicals Corporate Information, Head Office, and Major Competitors

Table 55. Dongcheng Biochemicals Major Business

Table 56. Dongcheng Biochemicals Neurodegenerative Disease Product and Solutions

Table 57. Dongcheng Biochemicals Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Hisun Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 59. Hisun Pharmaceutical Major Business

Table 60. Hisun Pharmaceutical Neurodegenerative Disease Product and Solutions

Table 61. Hisun Pharmaceutical Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Luye Pharma Corporate Information, Head Office, and Major Competitors

Table 63. Luye Pharma Major Business

Table 64. Luye Pharma Neurodegenerative Disease Product and Solutions

Table 65. Luye Pharma Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Ark Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 67. Ark Pharmaceutical Major Business

Table 68. Ark Pharmaceutical Neurodegenerative Disease Product and Solutions

Table 69. Ark Pharmaceutical Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Kanghong Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 71. Kanghong Pharmaceutical Major Business

Table 72. Kanghong Pharmaceutical Neurodegenerative Disease Product and Solutions

Table 73. Kanghong Pharmaceutical Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Huahai Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 75. Huahai Pharmaceutical Major Business

Table 76. Huahai Pharmaceutical Neurodegenerative Disease Product and Solutions

Table 77. Huahai Pharmaceutical Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 78. BORA PHARMACEUTICALS Corporate Information, Head Office, and Major Competitors

Table 79. BORA PHARMACEUTICALS Major Business

Table 80. BORA PHARMACEUTICALS Neurodegenerative Disease Product and Solutions

Table 81. BORA PHARMACEUTICALS Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 82. Global Neurodegenerative Disease Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 83. Global Neurodegenerative Disease Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 84. Breakdown of Neurodegenerative Disease by Company Type (Tier 1, Tier 2 and Tier 3)

Table 85. Neurodegenerative Disease Players Head Office, Products and Services Provided

Table 86. Neurodegenerative Disease Mergers & Acquisitions in the Past Five Years

Table 87. Neurodegenerative Disease New Entrants and Expansion Plans

Table 88. Global Neurodegenerative Disease Revenue (USD Million) by Type (2017-2022)

Table 89. Global Neurodegenerative Disease Revenue Share by Type (2017-2022)

Table 90. Global Neurodegenerative Disease Revenue Forecast by Type (2023-2028)

Table 91. Global Neurodegenerative Disease Revenue by Application (2017-2022)

Table 92. Global Neurodegenerative Disease Revenue Forecast by Application (2023-2028)

Table 93. North America Neurodegenerative Disease Revenue by Type (2017-2022) & (USD Million)

Table 94. North America Neurodegenerative Disease Revenue by Type (2023-2028) & (USD Million)

Table 95. North America Neurodegenerative Disease Revenue by Application (2017-2022) & (USD Million)

Table 96. North America Neurodegenerative Disease Revenue by Application (2023-2028) & (USD Million)

Table 97. North America Neurodegenerative Disease Revenue by Country (2017-2022) & (USD Million)

Table 98. North America Neurodegenerative Disease Revenue by Country (2023-2028) & (USD Million)

Table 99. Europe Neurodegenerative Disease Revenue by Type (2017-2022) & (USD Million)

Table 100. Europe Neurodegenerative Disease Revenue by Type (2023-2028) & (USD Million)

Table 101. Europe Neurodegenerative Disease Revenue by Application (2017-2022) & (USD Million)

Table 102. Europe Neurodegenerative Disease Revenue by Application (2023-2028) & (USD Million)

Table 103. Europe Neurodegenerative Disease Revenue by Country (2017-2022) & (USD Million)

Table 104. Europe Neurodegenerative Disease Revenue by Country (2023-2028) & (USD Million)

Table 105. Asia-Pacific Neurodegenerative Disease Revenue by Type (2017-2022) & (USD Million)

Table 106. Asia-Pacific Neurodegenerative Disease Revenue by Type (2023-2028) & (USD Million)

Table 107. Asia-Pacific Neurodegenerative Disease Revenue by Application (2017-2022) & (USD Million)

Table 108. Asia-Pacific Neurodegenerative Disease Revenue by Application (2023-2028) & (USD Million)

Table 109. Asia-Pacific Neurodegenerative Disease Revenue by Region (2017-2022) & (USD Million)

Table 110. Asia-Pacific Neurodegenerative Disease Revenue by Region (2023-2028) & (USD Million)

Table 111. South America Neurodegenerative Disease Revenue by Type (2017-2022) & (USD Million)

Table 112. South America Neurodegenerative Disease Revenue by Type (2023-2028) & (USD Million)

Table 113. South America Neurodegenerative Disease Revenue by Application (2017-2022) & (USD Million)

Table 114. South America Neurodegenerative Disease Revenue by Application (2023-2028) & (USD Million)

Table 115. South America Neurodegenerative Disease Revenue by Country (2017-2022) & (USD Million)

Table 116. South America Neurodegenerative Disease Revenue by Country (2023-2028) & (USD Million)

Table 117. Middle East & Africa Neurodegenerative Disease Revenue by Type (2017-2022) & (USD Million)

Table 118. Middle East & Africa Neurodegenerative Disease Revenue by Type (2023-2028) & (USD Million)

Table 119. Middle East & Africa Neurodegenerative Disease Revenue by Application (2017-2022) & (USD Million)

Table 120. Middle East & Africa Neurodegenerative Disease Revenue by Application (2023-2028) & (USD Million)

Table 121. Middle East & Africa Neurodegenerative Disease Revenue by Country (2017-2022) & (USD Million)

Table 122. Middle East & Africa Neurodegenerative Disease Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Neurodegenerative Disease Picture

Figure 2. Global Neurodegenerative Disease Revenue Market Share by Type in 2021

Figure 3. NMDA

Figure 4. SSRIs

Figure 5. Dopamine Inhibitors

Figure 6. Neurodegenerative Disease Revenue Market Share by Application in 2021

Figure 7. Parkinson’s Disease Picture

Figure 8. Huntington Disease Picture

Figure 9. Amyotrophic Lateral Sclerosis Picture

Figure 10. Alzheimer’s Disease Picture

Figure 11. Global Neurodegenerative Disease Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 12. Global Neurodegenerative Disease Revenue and Forecast (2017-2028) & (USD Million)

Figure 13. Global Neurodegenerative Disease Revenue Market Share by Region (2017-2028)

Figure 14. Global Neurodegenerative Disease Revenue Market Share by Region in 2021

Figure 15. North America Neurodegenerative Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Europe Neurodegenerative Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Asia-Pacific Neurodegenerative Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. South America Neurodegenerative Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Middle East and Africa Neurodegenerative Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Neurodegenerative Disease Market Drivers

Figure 21. Neurodegenerative Disease Market Restraints

Figure 22. Neurodegenerative Disease Market Trends

Figure 23. Novartis Recent Developments and Future Plans

Figure 24. Pfizer Recent Developments and Future Plans

Figure 25. Merck Serono Recent Developments and Future Plans

Figure 26. Biogen Idec Recent Developments and Future Plans

Figure 27. TEVA Recent Developments and Future Plans

Figure 28. UCB Recent Developments and Future Plans

Figure 29. Boehringer Ingelheim Recent Developments and Future Plans

Figure 30. Sanofi Recent Developments and Future Plans

Figure 31. GlaxoSmithKline Recent Developments and Future Plans

Figure 32. Livzon Pharmaceutical Recent Developments and Future Plans

Figure 33. Haisco Pharmaceutical Recent Developments and Future Plans

Figure 34. Jingxin Pharmaceutical Recent Developments and Future Plans

Figure 35. Dongcheng Biochemicals Recent Developments and Future Plans

Figure 36. Hisun Pharmaceutical Recent Developments and Future Plans

Figure 37. Luye Pharma Recent Developments and Future Plans

Figure 38. Ark Pharmaceutical Recent Developments and Future Plans

Figure 39. Kanghong Pharmaceutical Recent Developments and Future Plans

Figure 40. Huahai Pharmaceutical Recent Developments and Future Plans

Figure 41. BORA PHARMACEUTICALS Recent Developments and Future Plans

Figure 42. Global Neurodegenerative Disease Revenue Share by Players in 2021

Figure 43. Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 44. Global Top 3 Players Neurodegenerative Disease Revenue Market Share in 2021

Figure 45. Global Top 10 Players Neurodegenerative Disease Revenue Market Share in 2021

Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 47. Global Neurodegenerative Disease Revenue Share by Type in 2021

Figure 48. Global Neurodegenerative Disease Market Share Forecast by Type (2023-2028)

Figure 49. Global Neurodegenerative Disease Revenue Share by Application in 2021

Figure 50. Global Neurodegenerative Disease Market Share Forecast by Application (2023-2028)

Figure 51. North America Neurodegenerative Disease Sales Market Share by Type (2017-2028)

Figure 52. North America Neurodegenerative Disease Sales Market Share by Application (2017-2028)

Figure 53. North America Neurodegenerative Disease Revenue Market Share by Country (2017-2028)

Figure 54. United States Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Canada Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Mexico Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Europe Neurodegenerative Disease Sales Market Share by Type (2017-2028)

Figure 58. Europe Neurodegenerative Disease Sales Market Share by Application (2017-2028)

Figure 59. Europe Neurodegenerative Disease Revenue Market Share by Country (2017-2028)

Figure 60. Germany Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. France Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. United Kingdom Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Russia Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Italy Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Asia-Pacific Neurodegenerative Disease Sales Market Share by Type (2017-2028)

Figure 66. Asia-Pacific Neurodegenerative Disease Sales Market Share by Application (2017-2028)

Figure 67. Asia-Pacific Neurodegenerative Disease Revenue Market Share by Region (2017-2028)

Figure 68. China Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Japan Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. South Korea Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. India Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Southeast Asia Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. Australia Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. South America Neurodegenerative Disease Sales Market Share by Type (2017-2028)

Figure 75. South America Neurodegenerative Disease Sales Market Share by Application (2017-2028)

Figure 76. South America Neurodegenerative Disease Revenue Market Share by Country (2017-2028)

Figure 77. Brazil Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Argentina Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. Middle East and Africa Neurodegenerative Disease Sales Market Share by Type (2017-2028)

Figure 80. Middle East and Africa Neurodegenerative Disease Sales Market Share by Application (2017-2028)

Figure 81. Middle East and Africa Neurodegenerative Disease Revenue Market Share by Country (2017-2028)

Figure 82. Turkey Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 83. Saudi Arabia Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 84. UAE Neurodegenerative Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 85. Methodology

Figure 86. Research Process and Data Source